NIH R01 Funds Four-Site Randomized Trial of CG-Well 2 for Brain Injury Caregivers

News-Medical reported on October 6, 2026, drawing on a University of Cincinnati release, that Natalie Kreitzer, MD, associate professor of clinical medicine and vice chair of research in the university's Department of Emergency Medicine, has received a five-year, $2.5 million R01 grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development at NIH ^[1]. The award will support a multisite randomized clinical trial of CG-Well 2, a web- and telephone-based wellness intervention for family caregivers of people with moderate-to-severe traumatic brain injury (TBI), which the story defines as an interruption of normal brain function resulting from a forceful impact, jolt or penetrating object to the head ^[1]. Enrollment of up to 354 patient-caregiver pairs at four U.S. sites is expected to begin in early 2027 ^[1].

What the intervention contains

CG-Well, short for CareGiver Well, pairs structured web modules with phone coaching ^[1]. It comprises 43 modules, available online and in print, aimed at issues families tend to face in the first six months after a TBI, including stress, the Family and Medical Leave Act (FMLA), the move from the intensive care unit to rehabilitation or long-term acute care, and preparing the home for the patient's return ^[1]. The program is intended to reduce psychological distress and improve coping, against a background the story describes as high rates of anxiety, depression and burnout among caregivers ^[1].

Trial design as reported

Participants will be randomly assigned to one of two arms ^[1]. In the intervention arm, a trained interventionist with a social work or nursing background will call caregivers regularly and guide them through the tailored modules ^[1]. In the comparison arm, caregivers will have access only to publicly available information, and their calls will involve active listening without tailored content or advice ^[1].

The intervention is to start within two weeks of injury and continue through the transition from hospital to home ^[1]. Planned outcomes include caregiver health and well-being, caregiving appraisal (how a caregiver perceives their situation), patient outcomes, and the program's feasibility, acceptability and cost ^[1]. The sites are the University of Cincinnati, Ohio State University, Washington University in St. Louis and the University of Washington ^[1].

Why it matters to research and grants staff

The R01 builds on CG-Well 1, which enrolled 100 family caregivers under a five-year NIH K23, which the story identifies as a career development award, and the story describes the new grant as a major career milestone ^[1]. Kreitzer characterized that earlier study plainly: "It was a positive trial" ^[1]. She reported that caregivers in CG-Well had greater satisfaction and fewer psychological stress symptoms than those in the control condition ^[1]. The story gives no effect sizes, confidence intervals or methodological details for CG-Well 1, so the size of that benefit cannot be judged from this report ^[1].

The story describes CG-Well 2 as a rigorous evaluation of the intervention as a scalable program, run across four institutions with up to 354 patient-caregiver pairs compared with the 100 caregivers in the earlier study ^[1]. For health system and operations managers, the intervention spans the hospital-to-home transition within the first six months after injury, a period the story describes as especially intense for caregivers who may also be making decisions about treatment and rehabilitation ^[1].

What to watch next

• The start of enrollment, expected in early 2027 ^[1].
• Any peer-reviewed publication of CG-Well 1 results with effect sizes, which this story does not reference ^[1].
• Cost findings, which the trial will evaluate alongside feasibility and acceptability ^[1].
• Whether the tailored arm outperforms an active-listening comparison that also includes phone contact ^[1].

Limitations

This take rests on a single news story based on a university release, not on a peer-reviewed paper or trial protocol ^[1]. The story does not report a trial registration number, eligibility criteria, a primary outcome or a sample-size rationale, and the figure of 354 pairs is given as an upper bound on enrollment ^[1]. Statements about the earlier trial's benefit come from the investigator's own summary ^[1].